Across TCGA pan-cancer cohorts, TRAV38-1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TRAV38-1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRAV38-1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAV38-1 is over-expressed in tumor, although a few such as COAD and BLCA show the opposite, repressed pattern.

KIRC, COAD, and BRCA are the cancer types where TRAV38-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRAV38-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.699	<.001	11	view →
COAD	All	IV	−0.317	.016	4	view →
BRCA	All	All	+0.223	.002	4	view →
BLCA	Female	All	−0.472	.032	2	view →
LUSC	Male	III,IV	−1.092	.008	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TRAV38-1 RNA expression & survival · all TRAV38-1 data types